Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2010 1
2011 2
2013 1
2014 2
2015 2
2017 1
2018 2
2019 1
2021 2
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.
Borges IBP, Silva MG, Misse RG, Shinjo SK. Borges IBP, et al. Rheumatol Int. 2018 Feb;38(2):293-301. doi: 10.1007/s00296-017-3821-3. Epub 2017 Oct 12. Rheumatol Int. 2018. PMID: 29027009 Review.
Median age of the patients at time of diagnosis was 68 years. Seven patients had previously taken simvastatin 20 mg/day (exposure period from 2 days to 4 years) and two bezafibrate 100 mg/day (3-4 months). ...
Median age of the patients at time of diagnosis was 68 years. Seven patients had previously taken simvastatin 20 mg/day (exposure per …
Novel DZ-SIM Conjugate Targets Cancer Mitochondria and Prolongs Survival in Pancreatic Ductal Adenocarcinoma.
Ou Y, Wang R, Chu GC, Elmadbouh OHM, Lim A, Chung LW, Edderkaoui M, Zhang Y, Pandol SJ. Ou Y, et al. Adv Ther (Weinh). 2022 Oct;5(10):2200021. doi: 10.1002/adtp.202200021. Epub 2022 Jul 19. Adv Ther (Weinh). 2022. PMID: 36590644 Free PMC article.
We have developed a novel targeted therapy drug consisting of a tumor-targeting ligand, near-infrared (NIR) organic heptamethine carbocyanine dye (HMCD), and HMG-CoA inhibitor simvastatin (SIM), and assessed its efficacy in PDAC. PDAC cell specific targeting of DZ-SIM was …
We have developed a novel targeted therapy drug consisting of a tumor-targeting ligand, near-infrared (NIR) organic heptamethine carbocyanin …
Novel Mitochondria-Based Targeting Restores Responsiveness in Therapeutically Resistant Human Lung Cancer Cells.
Yin L, Zhang Y, Yin L, Ou Y, Lewis MS, Wang R, Zhau HE, Zhou Q, Chung LWK. Yin L, et al. Mol Cancer Ther. 2021 Dec;20(12):2527-2538. doi: 10.1158/1535-7163.MCT-20-1095. Epub 2021 Sep 28. Mol Cancer Ther. 2021. PMID: 34583981 Free PMC article.
This group of organic dyes can deliver therapeutic payloads specifically to tumor cells in the form of a chemical conjugate. We synthesized DZ-simvastatin (DZ-SIM) initially to target cholesterol biosynthesis in lung cancer cells. ...
This group of organic dyes can deliver therapeutic payloads specifically to tumor cells in the form of a chemical conjugate. We synthesized …
A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth.
Han B, Alonso-Valenteen F, Wang Z, Deng N, Lee TY, Gao B, Zhang Y, Xu Y, Zhang X, Billet S, Fan X, Shiao S, Bhowmick N, Medina-Kauwe L, Giuliano A, Cui X. Han B, et al. Mol Ther. 2022 Feb 2;30(2):672-687. doi: 10.1016/j.ymthe.2021.07.003. Epub 2021 Jul 16. Mol Ther. 2022. PMID: 34274535 Free PMC article.
Inhibiting cholesterol synthesis in lung-colonizing breast tumor cells by pulmonary administration of simvastatin-carrying HER3-targeting nanoparticles reduces angiogenesis and growth of lung metastases in a syngeneic TNBC mouse model. ...
Inhibiting cholesterol synthesis in lung-colonizing breast tumor cells by pulmonary administration of simvastatin-carrying HER3-targe …
Overcoming Resistance in Prostate Cancer Therapy Using a DZ-Simvastatin Conjugate.
Ou Y, Chu GC, Lyu J, Yin L, Lim A, Zhai N, Cui X, Lewis MS, Edderkaoui M, Pandol SJ, Wang R, Zhang Y. Ou Y, et al. Mol Pharm. 2024 Feb 5;21(2):873-882. doi: 10.1021/acs.molpharmaceut.3c00993. Epub 2024 Jan 16. Mol Pharm. 2024. PMID: 38229228 Free PMC article.
We have developed a delivery method using a tumor-cell-specific heptamethine carbocyanine dye (DZ) designed to transport therapeutic agents directly to tumor cells. This research evaluated simvastatin (SIM) as the antitumor payload because of its demonstrated chemopreventi …
We have developed a delivery method using a tumor-cell-specific heptamethine carbocyanine dye (DZ) designed to transport therapeutic agents …
Bioenergetic modulation overcomes glucocorticoid resistance in T-lineage acute lymphoblastic leukaemia.
Samuels AL, Heng JY, Beesley AH, Kees UR. Samuels AL, et al. Br J Haematol. 2014 Apr;165(1):57-66. doi: 10.1111/bjh.12727. Epub 2014 Jan 23. Br J Haematol. 2014. PMID: 24456076 Free article.
We found that oligomycin synergized with MPRED to sensitize cells otherwise resistant to GCs. Similarly we observed synergy between MPRED and simvastatin, an inhibitor of cholesterol metabolism. Collectively, our findings suggest that dual targeting of bioenergetic pathway …
We found that oligomycin synergized with MPRED to sensitize cells otherwise resistant to GCs. Similarly we observed synergy between MPRED an …
Safety of statin drugs in patients with dyslipidemia and stable systemic autoimmune myopathies.
Borges IBP, Shinjo SK. Borges IBP, et al. Rheumatol Int. 2019 Feb;39(2):311-316. doi: 10.1007/s00296-018-4215-x. Epub 2018 Dec 5. Rheumatol Int. 2019. PMID: 30519709
The median duration of the disease was 5.0 years. Twelve patients received simvastatin (10-60 mg/day), and 11 patients received atorvastatin (20-40 mg/day), and 1 patient received atorvastatin (10 mg/day) which was later replaced by simvastatin (20 mg/day). ...
The median duration of the disease was 5.0 years. Twelve patients received simvastatin (10-60 mg/day), and 11 patients received atorv …
Rhabdomyolysis with simvastatin and nefazodone.
Thompson M, Samuels S. Thompson M, et al. Am J Psychiatry. 2002 Sep;159(9):1607. doi: 10.1176/appi.ajp.159.9.1607. Am J Psychiatry. 2002. PMID: 12202291 No abstract available.
A pre-clinical model of resistance to induction therapy in pediatric acute lymphoblastic leukemia.
Samuels AL, Beesley AH, Yadav BD, Papa RA, Sutton R, Anderson D, Marshall GM, Cole CH, Kees UR, Lock RB. Samuels AL, et al. Blood Cancer J. 2014 Aug 1;4(8):e232. doi: 10.1038/bcj.2014.52. Blood Cancer J. 2014. PMID: 25083816 Free PMC article.
CMap analyses reinforced these features, identifying the cholesterol pathway inhibitor simvastatin (SVT) as a potential therapy to overcome resistance. Combined ex vivo with DEX, SVT was significantly synergistic, yet when administered in vivo with VXLD it did not delay le …
CMap analyses reinforced these features, identifying the cholesterol pathway inhibitor simvastatin (SVT) as a potential therapy to ov …
Impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer.
Wu BU, Chang J, Jeon CY, Pandol SJ, Huang B, Ngor EW, Difronzo AL, Cooper RM. Wu BU, et al. Am J Gastroenterol. 2015 Aug;110(8):1233-9. doi: 10.1038/ajg.2015.217. Epub 2015 Jul 21. Am J Gastroenterol. 2015. PMID: 26195180 Free PMC article.
Prior simvastatin but not lovastatin use was associated with improved survival (median 28.5 months (95% confidence limit (CL) 20.8, 38.4) for simvastatin vs. 12.9 months (9.6, 15.5) for lovastatin vs. 16.5 months (14.1, 18.9) for non-statin users; log-rank P=0.0035) …
Prior simvastatin but not lovastatin use was associated with improved survival (median 28.5 months (95% confidence limit (CL) 20.8, 3 …
14 results